Travere Therapeutics Inc. (tvtx 2.25 03/01/29)
13F holders, Q3 2024 (September 30)2holders
0new positions
0sold out
$1.56avg. 13F price*
At the end of Q3 2024, 2 institutions reported holding Travere Therapeutics Inc. (tvtx 2.25 03/01/29) in their 13F filings, unchanged from Q2 2024. 0 opened new positions and 0 sold out. The largest holders were Jane Street Group, LLC ($2.3M) and Nomura Holdings Inc. ($2.1M).
- Company
- Travere Therapeutics Inc. (tvtx 2.25 03/01/29)
- CUSIP
- 89422GAA5
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q2 2024 → Q3 2024: 629,134 shares sold, net −629,134 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Jane Street Group, LLC | 0.00% | Reduce -7.1% | 2,633,000 | $2.3M |
| Nomura Holdings Inc. | 0.02% | Reduce -74.5% | 146,736 | $2.1M |
"% of holder's portfolio" is TRAVERE THERAPEUTICS INC (TVTX 2.25 03/01/29)'s weight in each manager's 13F, not the share of Travere Therapeutics Inc. (tvtx 2.25 03/01/29) the manager owns.